LMWH is typically administered via subcutaneous injection. The dosing in neonates can be challenging due to their unique physiology, and it often requires careful monitoring and adjustment. The starting dose is generally based on the neonate's weight, and subsequent doses are adjusted based on anti-Xa levels to ensure therapeutic efficacy while minimizing the risk of bleeding.
